The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Postmenopausal Hormone Therapy and Risk of Idiopathic Venous Thromboembolism: Results From the E3N Cohort Study
Abstract
Objective— Oral estrogen therapy increases venous thromboembolism risk among postmenopausal women. Although recent data showed transdermal estrogens may be safe with respect to thrombotic risk, the impact of the route of estrogen administration and concomitant progestogens is not fully established. Methods and Results— We used data from the E3N French prospective cohort of women born between 1925 and 1950 and biennially followed by questionnaires from 1990. Study population consisted of 80 308 postmenopausal women (average follow-up: 10.1 years) including 549 documented idiopathic first venous thromboembolism. Hazard ratios (HR) and 95% confidence intervals (CI) were estimated using Cox proportional models. Compared to never-users, past-users of hormone therapy had no increased thrombotic risk (HR=1.1; 95% CI: 0.8 to 1.5). Oral not transdermal estrogens were associated with increased thrombotic risk (HR=1.7; 95% CI: 1.1 to 2.8 and HR=1.1; 95% CI: 0.8 to 1.8; homogeneity: P =0.01). The thrombotic risk significantly differed by concomitant progestogens type (homogeneity: P <0.01): there was no significant association with progesterone, pregnanes, and nortestosterones (HR=0.9; 95% CI: 0.6 to 1.5, HR=1.3; 95% CI: 0.9 to 2.0 and HR=1.4; 95% CI: 0.7 to 2.4). However, norpregnanes were associated with increased thrombotic risk (HR=1.8; 95% CI: 1.2 to 2.7). Conclusions— In this large study, we found that route of estrogen administration and concomitant progestogens type are 2 important determinants of thrombotic risk among postmenopausal women using hormone therapy. Transdermal estrogens alone or combined with progesterone might be safe with respect to thrombotic risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Canonico, M., Oger, E., Plu-Bureau, G., Conard, J., Meyer, G., Lévesque, H., Trillot, N., Barrellier, M.-T., Wahl, D., Emmerich, J., et al. (2007) · Circulation · doi:10.1161/circulationaha.106.642280 · Cited by 864
Self-citationRisk of venous thromboembolism in users of hormone replacement therapy
Daly, E., Vessey, M. P., Hawkins, M. M., Carson, J. L., Gough, P., & Marsh, S. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07113-9 · Cited by 819
Nelson, H. D. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60346-3 · Cited by 729
Scarabin, P.-Y., Oger, E., & Plu-Bureau, G. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14066-4 · Cited by 714
Self-citationEstrogen plus progestin and risk of venous thrombosis
Cushman, M. (2004) · JAMA · doi:10.1001/jama.292.13.1573 · Cited by 632
Jick, H., Derby, L. E., Myers, M. W., Vasilakis, C., & Newton, K. M. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07114-0 · Cited by 602
Canonico, M., Plu-Bureau, G., Lowe, G. D. O., & Scarabin, P.-Y. (2008) · BMJ · doi:10.1136/bmj.39555.441944.be · Cited by 569
Self-citationEvidence from randomised trials on the long-term effects of hormone replacement therapy
Beral, V., Banks, E., & Reeves, G. (2002) · The Lancet · doi:10.1016/s0140-6736(02)11032-4 · Cited by 487
Cited by
2016 IMS Recommendations on women’s midlife health and menopause hormone therapy
Baber, R. J., Panay, N., & Fenton, A. (2016) · Climacteric · doi:10.3109/13697137.2015.1129166 · Cited by 964
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Estrogen and the cardiovascular system
Knowlton, A. A., & Lee, A. R. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.03.007 · Cited by 489
Vinogradova, Y., Coupland, C., & Hippisley-Cox, J. (2019) · BMJ · doi:10.1136/bmj.k4810 · Cited by 433
Cross-sex Hormones and Acute Cardiovascular Events in Transgender Persons: A Cohort Study
Getahun, D., Nash, R., Flanders, W. D., Baird, T. C., Becerra-Culqui, T. A., Cromwell, L., Hunkeler, E., Lash, T. L., Millman, A., Quinn, V. P., et al. (2018) · Annals of Internal Medicine · doi:10.7326/m17-2785 · Cited by 431
Stanczyk, F. Z., Hapgood, J. P., Winer, S., & Mishell, D. R. (2013) · Endocrine Reviews · doi:10.1210/er.2012-1008 · Cited by 429
Kujovich, J. L. (2011) · Genetics in Medicine · doi:10.1097/gim.0b013e3181faa0f2 · Cited by 419
Schumacher, M., Mattern, C., Ghoumari, A., Oudinet, J. P., Liere, P., Labombarda, F., Sitruk-Ware, R., De Nicola, A. F., & Guennoun, R. (2014) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.09.004 · Cited by 355
Hamoda, H., Panay, N., Pedder, H., Arya, R., & Savvas, M. (2020) · Post Reproductive Health · doi:10.1177/2053369120957514 · Cited by 192
Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis
Mohammed, K., Abu Dabrh, A. M., Benkhadra, K., Al Nofal, A., Carranza Leon, B. G., Prokop, L. J., Montori, V. M., Faubion, S. S., & Murad, M. H. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2237 · Cited by 183
Hormone Therapy in Menopause: Concepts, Controversies, and Approach to Treatment
Flores, V. A., Pal, L., & Manson, J. E. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab011 · Cited by 174
Hormone replacement therapy – Current recommendations
Vigneswaran, K., & Hamoda, H. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2021.12.001 · Cited by 151
HRT for women with premature ovarian insufficiency: a comprehensive review
Webber, L., Anderson, R. A., Davies, M., Janse, F., & Vermeulen, N. (2017) · Human Reproduction Open · doi:10.1093/hropen/hox007 · Cited by 141
“In older postmenopausal women, transdermal estrogen has a lower risk of myocardial infarction, VTE, stroke and breast cancer (Lokkegaard et al., 2008; Nelson, 2009; Canonico et al., 2010; Divasta and Gordon, 2010; Renoux et al., 2010a, b; Goodman, 2012).”
BackgroundEffects of transdermal versus oral hormone replacement therapy in postmenopause: a systematic review
Goldštajn, M. Š., Mikuš, M., Ferrari, F. A., Bosco, M., Uccella, S., Noventa, M., Török, P., Terzic, S., Laganà, A. S., & Garzon, S. (2022) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-022-06647-5 · Cited by 111
Bergendal, A., Kieler, H., Sundström, A., Hirschberg, A. L., & Kocoska-Maras, L. (2016) · Menopause · doi:10.1097/gme.0000000000000611 · Cited by 90
Premature menopause and risk of neurological disease: Basic mechanisms and clinical implications
Scott, E. L., Zhang, Q.-G., Vadlamudi, R. K., & Brann, D. W. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2014.01.013 · Cited by 36
Turner syndrome through the lens of a gynaecologist
Jivraj, S., & Stillwell, S. (2021) · Post Reproductive Health · doi:10.1177/2053369120958593 · Cited by 5
Metadata
- Authors
- Canonico, M., Fournier, A., Carcaillon, L., Olié, V., Plu-Bureau, G., Oger, E., Mesrine, S., Boutron-Ruault, M.-C., Clavel-Chapelon, F., & Scarabin, P.-Y.
- Venue
- Arteriosclerosis, Thrombosis, and Vascular Biology
- Published
- 2010-02
- Volume
- 30
- Issue
- 2
- Pages
- 340-345
- ISSN
- 1079-5642 (ISSN-L)
- 1524-4636
- OpenAlex
- W2153062627
- Cited by
- 272
- References
- 42
- FWCI
- 12.18
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.